ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2485

Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

April Jorge1, Baijun Zhou1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

Meeting: ACR Convergence 2023

Keywords: comparative effectiveness, depression, mental health, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: SLE – Treatment II: Nonrenal

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of serious depression and suicidality than placebo. (Sheikh S et al, Lancet Rheumatol. 2020). However, the comparative risk of psychiatric outcomes between belimumab versus oral immunosuppressants is unknown.

Methods: We conducted a comparative cohort study of adult patients with SLE who initiated treatment with belimumab versus an oral immunosuppressant (azathioprine [AZA], methotrexate [MTX], or mycophenolate [MMF]) between 2011-2021 using observational data from TriNetX, a United States multi-center electronic health records database. We excluded patients with lupus nephritis prior to the index date of treatment initiation. The outcomes of interest were hospitalization for depression and attempted suicide. We designed and emulated a hypothetical target trial to estimate the cumulative incidence and hazard ratios (HRs) of these outcomes associated with belimumab initiation versus each of the oral immunosuppressants. In three parallel analyses, we used propensity score overlap weighting to balance covariates, including age, sex, race/ethnicity, geographic region, year of initiation, use of concomitant SLE medications (glucocorticoids, hydroxychloroquine, rituximab, cyclophosphamide, other immunosuppressants), Charlson comorbidity index, SLE severity index, chronic kidney disease, healthcare utilization, and prior diagnoses of mood disorders. In a secondary population excluding patients with prior mood disorders, we also assessed the outcome of new onset depression. Patients were followed until the earliest of the outcome, death, end of the study period (August 31, 2021), or two years after treatment initiation. In a per-protocol analysis, patients were additionally censored for discontinuation of the assigned treatment or initiation of the comparator, and we adjusted for adherence to assigned treatment using inverse probability of treatment weighting.

Results: Of 91,425 patients with SLE, we compared 2,434 and 5,644 initiators of belimumab and AZA, (Table 1), 2,163 and 7,224 initiators of belimumab and MTX, and 2,431 and 6,350 initiators of belimumab and MMF, respectively. After propensity score overlap weighting, covariates were balanced in each comparison. 95% were female; the mean age was 44 years. Attempted suicide was rare, with fewer than 10 events in each treatment group. There were no differences in the risk of hospitalized depression among belimumab initiators and initiators of AZA or MTX (Table 2). The risk of hospitalization for depression was lower for belimumab than MMF users (HR 0.70 [95% CI 0.52-0.95]). There was no difference in the risk of new onset depression among patients without a prior history of mood disorders (Table 3).

Conclusion: In this multi-center observational SLE cohort, we found that belimumab use was not associated with an increased risk of serious psychiatric events compared with oral immunosuppressants for SLE. This provides real-world reassurance of the safety of this medication for the treatment of SLE.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Jorge: None; B. Zhou: None; Y. Zhang: None; H. Choi: Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2.

To cite this abstract in AMA style:

Jorge A, Zhou B, Zhang Y, Choi H. Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/comparative-risk-of-serious-psychiatric-events-with-belimumab-versus-oral-immunosuppressant-use-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-risk-of-serious-psychiatric-events-with-belimumab-versus-oral-immunosuppressant-use-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology